Over the course of the past week or so, the Regen BioPharma Inc (OTCMKTS:RGBP) stock has emerged as one of the biggest gainers in the capital markets. The stock has managed to generate gains of as much as 1500% during the past week and in light of such enormous gains, it is likely that the stock is going to come under the radar of new investors.
There has been no fresh news about the company this week so far but the rally in the stock has been brought about by a major development from last week. The Regen Biopharma stock went on this remarkable rally after the company announced the signing of a licensing deal regarding its pancreatic cancer treatment.
In this regard, it is necessary to point out that before the rally the stock was what is called a ‘triple zero’ stock. In these types of stocks, such enormous rallies are not uncommon. However, it might still be a good idea for investors to take a closer look at what actually happened. The company had a market cap of only $10 million last week but following the rally, the market cap of Regan Biopharma went past $1 billion.
Back on April 7, the company announced that it reached an agreement with Oncology Pharma. According to the provisions of the agreement reached between the two parties, Oncology Pharma is going to get the rights to the intellectual property pertaining to the pancreatic cancer therapies developed by Regen. It is interesting to note that after the announcement had been made, investors in Oncology Pharma had also been suitably optimistic.
The stock price rallied by as much as 8% after the news emerged about the licensing deal. Regen is going to be paid $55,000 as a non-refundable fee by April 20, 2021. Additionally, the company is also going to be paid 5% of net sales as royalties.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.